The class of "RIKEN cDNA 4933416I08 Gene Inhibitors" is characterized by a diverse array of chemical compounds, each exhibiting unique biochemical properties that enable them to modulate various cellular signaling pathways. These compounds, though not directly linked to the RIKEN cDNA 4933416I08 gene due to the lack of specific scientific data, are known to influence key cellular processes that could indirectly impact the function of proteins encoded by this gene.
For instance, Axitinib and Pazopanib are known to inhibit tyrosine kinases involved in cell growth and angiogenesis, potentially altering signaling pathways that the RIKEN cDNA 4933416I08-encoded protein may participate in. Bosutinib and Dasatinib target specific tyrosine kinases like Src/Abl, thereby influencing cell proliferation and survival. Similarly, Crizotinib's inhibition of ALK, MET, and ROS1 tyrosine kinases can affect pathways related to cell differentiation and growth.
Erlotinib and Gefitinib specifically inhibit the EGFR tyrosine kinase, a key player in many cellular signaling pathways related to proliferation and apoptosis. Imatinib, targeting BCR-ABL, c-KIT, and PDGFR tyrosine kinases, impacts multiple pathways involved in cell proliferation and survival. Lapatinib's dual inhibition of EGFR and HER2 tyrosine kinases makes it significant in affecting pathways related to cell growth and survival.
Nilotinib's selective inhibition of BCR-ABL tyrosine kinase highlights its potential in influencing specific cell signaling pathways. Sorafenib and Sunitinib, by inhibiting multiple tyrosine kinases, exhibit a broad spectrum of activity affecting processes like cell proliferation, angiogenesis, and apoptosis.
These chemicals represent a comprehensive approach to understanding and modulating cellular signaling pathways. They provide insights into how different biochemical interactions can influence the activity of proteins encoded by genes like the RIKEN cDNA 4933416I08. By acting at various levels of cellular signaling, from receptor tyrosine kinases to downstream signaling molecules, these inhibitors contribute to our understanding of the complex network of interactions within the cell. Their diverse mechanisms of action highlight the intricate balance of cellular processes and offer a window into the potential regulation of proteins similar to those encoded by the RIKEN cDNA 4933416I08 gene.
Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Inhibiteur de tyrosine kinase à large spectre, affectant potentiellement de multiples voies de signalisation impliquées dans la prolifération et la survie cellulaires. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Inhibe la tyrosine kinase de l'EGFR, affectant potentiellement les voies de la prolifération cellulaire et de l'apoptose. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Cible la tyrosine kinase EGFR, influençant potentiellement les voies de signalisation impliquées dans la croissance et la division cellulaires. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibe les tyrosines kinases BCR-ABL, c-KIT et PDGFR, affectant potentiellement les voies de la prolifération cellulaire et de l'apoptose. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Double inhibiteur des tyrosines kinases EGFR et HER2, affectant potentiellement les voies de croissance et de survie des cellules. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Inhibe sélectivement la tyrosine kinase BCR-ABL, influençant potentiellement la prolifération cellulaire et les voies de signalisation. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Inhibe les tyrosines kinases VEGFR, PDGFR et KIT, affectant potentiellement l'angiogenèse et les voies de croissance cellulaire. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibe de multiples tyrosines kinases, affectant potentiellement les voies de la prolifération cellulaire, de l'angiogenèse et de l'apoptose. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibe diverses tyrosines kinases, ce qui peut avoir un impact sur l'angiogenèse et la prolifération des cellules tumorales. |